All of the Phase 2b patients have aggressive stage III and IV ovarian cancer. Progression usually occurs within the first year, those in second line remission progress sooner. There will be comparative data between arms as to who progressed first and fastest.
Interim results aren't released for fun. They're carefully planned and measured to give the best indication of the trial at the predetermined interval (too many interim results muddies the data, which is why the "multiple looks" approach is frowned upon.)
So Hypetastic - Efficacy data, which has been pointed out to you a number of times already, will be a significant reason for data collection at this point.
PRR Price at posting:
9.8¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)